Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Non-Current Assets (2020 - 2023)

Cullinan Therapeutics has reported Non-Current Assets over the past 4 years, most recently at $18.0 million for Q3 2023.

  • Quarterly results put Non-Current Assets at $18.0 million for Q3 2023, down 48.82% from a year ago — trailing twelve months through Sep 2023 was $244.3 million (down 27.13% YoY), and the annual figure for FY2022 was $86.6 million, down 38.38%.
  • Non-Current Assets for Q3 2023 was $18.0 million at Cullinan Therapeutics, down from $23.7 million in the prior quarter.
  • Over the last five years, Non-Current Assets for CGEM hit a ceiling of $140.6 million in Q4 2021 and a floor of $2.4 million in Q4 2020.
  • Median Non-Current Assets over the past 4 years was $65.5 million (2022), compared with a mean of $71.6 million.
  • Biggest five-year swings in Non-Current Assets: soared 5686.87% in 2021 and later plummeted 71.77% in 2022.
  • Cullinan Therapeutics' Non-Current Assets stood at $2.4 million in 2020, then soared by 5686.87% to $140.6 million in 2021, then plummeted by 38.38% to $86.6 million in 2022, then plummeted by 79.23% to $18.0 million in 2023.
  • The last three reported values for Non-Current Assets were $18.0 million (Q3 2023), $23.7 million (Q2 2023), and $116.0 million (Q1 2023) per Business Quant data.